13.07.2015 Views

Guidelines for Complications of Cancer Treatment Vol VIII Part B

Guidelines for Complications of Cancer Treatment Vol VIII Part B

Guidelines for Complications of Cancer Treatment Vol VIII Part B

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Useful radiation therapy planning parameters <strong>for</strong>identifying at risk casesIn conventional fractionation, various studies have implicatedpercent <strong>of</strong> the total lung volume exceeding 20 Gy (V20), theeffective volume (Veff) and the total lung volume mean dose,and location <strong>of</strong> the tumor primary (upper versus lower lobes)to be statistically significant relative to the development <strong>of</strong> >Grade 2 pneumonitis. (graham) Continuous hyperfractionatedaccelerated radiotherapy (CHART) involves giving 3 fractions<strong>of</strong> small dose per fraction per day <strong>for</strong> 12 days.(Peter Jenkins).In relation to acute radiation pneumonitis, CHART has beenshown to have a superior therapeutic index than conventionallyfractionated radiotherapy. V20 and mean lung dose are usefulfactors <strong>for</strong> predicting the risk <strong>of</strong> pulmonary complications inCHART therapy.Management <strong>of</strong> Pneumonitis and Lung fibrosisCorticosteroids <strong>for</strong>m the mainstay in recovery frompneumonitis caused by varied etiological agents. In generalthe treatment <strong>for</strong> pneumonits is a dose <strong>of</strong> 30-60 mg <strong>of</strong>prednisone per day <strong>for</strong> 2-3 weeks with subsequent tapering.Superadded infection should be treated by antibiotics, oxygenmay be required in severe cases along with other supportivemeasures. Smoking should be strictly avoided. There shouldbe awareness about the risks <strong>of</strong> general anaesthesia in suchpatients.Future directionsOur understanding <strong>of</strong> the molecular mechanisms underlyingradiation lung injury continues to evolve. Predicting whichpatients will suffer from this complication is a challenge atpresent. Ideally, individual phenotype- and genotype-basedrisk pr<strong>of</strong>iles should be able to identify patients who aresensitive to RP. The predictive power <strong>of</strong> biomarkers might beincreased if they are coupled with radiogenomics, e.g.,320

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!